CAJ | 학술논문

目的观察重组人脑利钠肽(rhBNP)治疗急性非ST段抬高型心肌梗死(NSTEMI)并发心力衰竭的疗效和安全性.方法选取80例NSTEMI并发心力衰竭患者,根据随机数字表法分为观察组和对照组,每组各40例.观察组给予静脉注射rhBNP治疗,对照组静脉注射硝酸甘油.比较两组用药前后生命体征、呼吸困难程度、脑钠肽(BNP)、相关血流动力学指标的变化及不良反应.结果观察组治疗总有效率87.5％(35/40),高于对照组的50.0％ (20/40)(x2=13.09,P＜0.05).观察组治疗后左室射血分数(LVEF)和每小时平均尿量均较治疗前显著升高(t=26.40、3.22,均P＜0.05),BNP水平较治疗前显著降低(t=14.11,P＜0.05).而对照组治疗前后LVEF、BNP和尿量均无明显变化.结论 rhBNP治疗NSTEMI并发心力衰竭疗效显著,副作用少,具有较高的临床应用价值.
목적 관찰중조인뇌리납태(rhBNP)치료급성비ST단태고형심기경사(NSTEMI)병발심력쇠갈적료효화안전성.방법 선취80례NSTEMI병발심력쇠갈환자,근거수궤수자표법분위관찰조화대조조,매조각40례.관찰조급여정맥주사rhBNP치료,대조조정맥주사초산감유.비교량조용약전후생명체정、호흡곤난정도、뇌납태(BNP)、상관혈류동역학지표적변화급불량반응.결과 관찰조치료총유효솔87.5％(35/40),고우대조조적50.0％ (20/40)(x2=13.09,P＜0.05).관찰조치료후좌실사혈분수(LVEF)화매소시평균뇨량균교치료전현저승고(t=26.40、3.22,균P＜0.05),BNP수평교치료전현저강저(t=14.11,P＜0.05).이대조조치료전후LVEF、BNP화뇨량균무명현변화.결론 rhBNP치료NSTEMI병발심력쇠갈료효현저,부작용소,구유교고적림상응용개치.
Objective To investigate the the efficacy and safety of recombinant human brain natriuretic peptide (rhBNP) in the treatment of acute non-ST-segment elevation myocardial infarction patients with heart failure.Methods 80 patients with heart failure caused by acute non-ST-segment elevation myocardial infarction were chosen,they were divided into the observation group and control group based on a random number table,each group included 40 patients.The observation group were treated with intravenous injection of recombinant human brain natriuretic peptide,the control group were treated with intravenous nitroglycerin.vital signs,dyspnea,brain natriuretic peptide (BNP),associated hemodynamic changes and adverse reactions of two groups were compared before and after treatment.Results The total effective rate in observation group was 87.5％ (35/40),which were significantly higher than 50.0％ (20/40) of the control group,there were significant difference (x2 =13.09,P ＜ 0.05).In the observation group,after treatment,the left ventricular ejection fraction (LVEF) and average hourly urine output were significantly higher than those of before treatment (t =26.40,3.22,all P ＜ 0.05),and the brain natriuretic peptide (BNP) concentration levels were significantly lower than those of before treatment (t =14.11,all P ＜ 0.05).The control group before and after treatment LVEF,BNP and changes in urine levels were not significantly.Conclusion In the treatment of heart failure caused by acute non-ST-segment elevation myocardial infarction,the recombinant human brain natriuretic peptide (rhBNP) has significant effect,feasible and safe with few side effects,which has a high clinical value.